^
Association details:
| Biomarker: | FGFR2-ZMYM4 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
Excerpt:
...a 59-year-old female with a FGFR2-ZMYM4 fusion-positive ICC who presented with a dominant 15 cm liver mass and metastases to her liver and lungs. She achieved a maximum response of −50% on second-line BGJ398 treatment. Scans at 6 months showed a mixed response with regression of the dominant mass and progression of satellite liver lesions.
DOI:
https://dx.doi.org/10.1158%2F2159-8290.CD-19-0182
